AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20664489 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 58
Study 20664489 — intervention group
Group type: COMPARATOR
Intervention: Higher doses of olanzapine
Number of subjects: 58
Study 18604601 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive affective stimuli
Number of subjects: 47
Study 18604601 — intervention group
Group type: EXPERIMENTAL
Intervention: Beverage cue
Number of subjects: 47
Study 18604601 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative affective stimuli
Number of subjects: 47
Study 18604601 — intervention group
Group type: COMPARATOR
Intervention: Interaction effects between affect and beverage conditions
Number of subjects: 47
Study 17172427 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg twice daily for 5 to 15 days before surgery
Number of subjects: 17
Study 17172427 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib for 28 days in xenografted mice
Number of subjects: 17
Study 17172427 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 17
Study 14517580 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate concentrations (1-100 microg/mL)
Number of subjects: 19
Study 14517580 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (pair-matched for age, reproductive and smoking status)
Number of subjects: 19
Study 11081318 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal dihydrotestosterone (DHT) treatment for 12 weeks
Number of subjects: 10
Study 11081318 — intervention group
Group type: COMPARATOR
Intervention: Placebo (not explicitly mentioned but implied as control)
Number of subjects: 10
Study 8721258 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg riluzole
Number of subjects: 20
Study 8721258 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg riluzole
Number of subjects: 20
Study 8721258 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg riluzole
Number of subjects: 20
Study 8721258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1416129 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia by epidural infusion of buprenorphine (3 micrograms/mL) with 0.03% bupivacaine
Number of subjects: 23
Study 1416129 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled analgesia by epidural infusion of fentanyl (2 micrograms/mL) with 0.03% bupivacaine
Number of subjects: 23
Study 3986085 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral secoverine hydrochloride
Number of subjects: 12
Study 3986085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30908367 — intervention group
Group type: COMPARATOR
Intervention: Sham + Pla
Number of subjects: 15
Study 30908367 — intervention group
Group type: EXPERIMENTAL
Intervention: a‐tDCS + Pla
Number of subjects: 15
Study 30908367 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham + Caff
Number of subjects: 15
Study 30908367 — intervention group
Group type: EXPERIMENTAL
Intervention: a‐tDCS + Caff
Number of subjects: 15
Study 30396975 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectus sheath block (RSB) analgesia - single-dose
Number of subjects: 56
Study 30396975 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectus sheath block (RSB) analgesia - repeated-dose
Number of subjects: 56
Study 30396975 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectus sheath block (RSB) analgesia - continuous infusion
Number of subjects: 56
Study 30396975 — intervention group
Group type: COMPARATOR
Intervention: Control group (no RSB analgesia)
Number of subjects: 56
Study 26969158 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital play interventions
Number of subjects: 304
Study 26969158 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 304
Study 25223547 — intervention group
Group type: EXPERIMENTAL
Intervention: One-day bowel preparation with Miralax®
Number of subjects: 32
Study 25223547 — intervention group
Group type: COMPARATOR
Intervention: Three-day bowel preparation with Miralax®
Number of subjects: 32
Study 22344064 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 29
Study 22344064 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 29
Study 20045611 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-toed, elastic, class III compression device (Tubulcus)
Number of subjects: 131
Study 20045611 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component bandaging system (Tubulcus + one elastic bandage)
Number of subjects: 131
Study 20045611 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component bandaging system (Tubulcus + two elastic bandages)
Number of subjects: 131
Study 20045611 — intervention group
Group type: COMPARATOR
Intervention: Single-component compression system (group A)
Number of subjects: 131
Study 20045611 — intervention group
Group type: COMPARATOR
Intervention: Multi-component compression systems (groups B and C)
Number of subjects: 131
Study 18070300 — intervention group
Group type: EXPERIMENTAL
Intervention: Transesophageal cardioversion
Number of subjects: 60
Study 18070300 — intervention group
Group type: EXPERIMENTAL
Intervention: Transthoracic cardioversion
Number of subjects: 60
Study 15668847 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient rehabilitation
Number of subjects: 0
Study 15668847 — intervention group
Group type: COMPARATOR
Intervention: Inpatient rehabilitation
Number of subjects: 0
Study 11007446 — intervention group
Group type: COMPARATOR
Intervention: placebo-8 hr time-in-bed (TIB)
Number of subjects: 17
Study 11007446 — intervention group
Group type: COMPARATOR
Intervention: placebo-4 hr TIB
Number of subjects: 17
Study 11007446 — intervention group
Group type: COMPARATOR
Intervention: placebo-0 hr TIB
Number of subjects: 17
Study 11007446 — intervention group
Group type: EXPERIMENTAL
Intervention: diphenhydramine 50 mg-8 hr TIB
Number of subjects: 17
Study 9076381 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombin supplementation
Number of subjects: 50
Study 9076381 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 8436497 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone (1 mg/kg a day divided into 3 doses) for 12 weeks
Number of subjects: 40
Study 8436497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 8436497 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone (after washout period for 12 weeks)
Number of subjects: 40
Study 8436497 — intervention group
Group type: COMPARATOR
Intervention: Placebo (after washout period for 12 weeks)
Number of subjects: 40
Study 3743531 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine alarm (UA) alone
Number of subjects: 50
Study 3743531 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine alarm (UA) plus retention control training (RCT)
Number of subjects: 50
Study 3743531 — intervention group
Group type: COMPARATOR
Intervention: Control group (premature termination)
Number of subjects: 50
Study 29278443 — intervention group
Group type: EXPERIMENTAL
Intervention: Solution-focused approach interview technique (8 interviews at 2-week intervals, 30-45 min each)
Number of subjects: 32
Study 29278443 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 32
Study 29278443 — intervention group
Group type: EXPERIMENTAL
Intervention: Solution-focused approach interview technique
Number of subjects: 32
Study 26617254 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity endurance training (70-85% of heart rate reserve; n=38)
Number of subjects: 106
Study 26617254 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity endurance training (40-55% heart rate reserve; n=32)
Number of subjects: 106
Study 26617254 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=36)
Number of subjects: 106
Study 23436863 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic core needle biopsy (CNB) or vacuum‐assisted biopsy (VAB) for DIN 1A
Number of subjects: 239
Study 23436863 — intervention group
Group type: COMPARATOR
Intervention: Imaging follow-up for patients who did not undergo surgical excision
Number of subjects: 239
Study 21631932 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 0
Study 21631932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18098228 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-negative breast cancer (FDG-PET imaging)
Number of subjects: 88
Study 18098228 — intervention group
Group type: COMPARATOR
Intervention: ER+/PR+/HER2- breast cancer (FDG-PET imaging)
Number of subjects: 88
Study 18098228 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-negative breast cancer (tumor size < or = 2 cm)
Number of subjects: 88
Study 18098228 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-negative breast cancer (tumor size > 2 cm)
Number of subjects: 88
Study 18098228 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-negative breast cancer (grade 3 tumors)
Number of subjects: 88
Study 18098228 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-negative breast cancer (stage II disease)
Number of subjects: 88
Study 16579997 — intervention group
Group type: EXPERIMENTAL
Intervention: CC+MET
Number of subjects: 31
Study 16579997 — intervention group
Group type: COMPARATOR
Intervention: CC
Number of subjects: 31
Study 12690917 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon-coated stent (Carbostent, n = 23)
Number of subjects: 44
Study 12690917 — intervention group
Group type: COMPARATOR
Intervention: Uncoated stent (Multilink, n = 21)
Number of subjects: 44
Study 12690917 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon-coated stent (Carbostent)
Number of subjects: 44
Study 12690917 — intervention group
Group type: COMPARATOR
Intervention: Uncoated stent (Multilink)
Number of subjects: 44
Study 11135795 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-child autotutorial (PCAT) programme, a 10-week home-based self-instruction nutrition education programme
Number of subjects: 227
Study 11135795 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition counselling from a registered dietitian
Number of subjects: 227
Study 11135795 — intervention group
Group type: COMPARATOR
Intervention: At-risk control group
Number of subjects: 227
Study 11135795 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education (PCAT or counselling)
Number of subjects: 227
Study 9100622 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibopamine 100 mg three times daily
Number of subjects: 1906
Study 9100622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1906
Study 7505523 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous diluted intravesical instillation of bleomycin (120 mg/2,000 ml saline solution/day for 3 days), instillation BCG (40 mg/40 ml saline solution/weekly 6 times), and UFT (400 mg orally/day for 2 years maximum)
Number of subjects: 63
Study 7505523 — intervention group
Group type: COMPARATOR
Intervention: No BCG instillation (UFT and bleomycin only)
Number of subjects: 63
Study 3569448 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg ambroxol daily
Number of subjects: 14
Study 3569448 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 28937912 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum contraceptive use
Number of subjects: 161
Study 28937912 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance use
Number of subjects: 161
Study 28937912 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid repeat pregnancy
Number of subjects: 161
Study 27553626 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive quality improvement intervention for back pain including 6 one-hour training sessions for physicians, 5 days of training for physical therapists, individualized and group coaching of clinicians, and integration of the STarT Back tool into the electronic health record.
Number of subjects: 6
Study 27553626 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving standard care without the intensive quality improvement intervention.
Number of subjects: 6
Study 24929048 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral male faces as conditioned threat and safety cues
Number of subjects: 120
Study 24929048 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral female faces as conditioned threat and safety cues
Number of subjects: 120
Study 24929048 — intervention group
Group type: EXPERIMENTAL
Intervention: Fearful face paired with a shrieking scream as unconditioned stimulus
Number of subjects: 120
Study 22147796 — intervention group
Group type: EXPERIMENTAL
Intervention: Male circumcision
Number of subjects: 740
Study 22147796 — intervention group
Group type: COMPARATOR
Intervention: Control (no male circumcision)
Number of subjects: 740
Study 22147796 — intervention group
Group type: EXPERIMENTAL
Intervention: Male circumcision among female partners of HSV‐2-positive males
Number of subjects: 740
Study 22147796 — intervention group
Group type: COMPARATOR
Intervention: Control (no male circumcision) among female partners of HSV‐2-positive males
Number of subjects: 740
Study 20813866 — intervention group
Group type: EXPERIMENTAL
Intervention: Online predilution hemofiltration (HF)
Number of subjects: 146
Study 20813866 — intervention group
Group type: EXPERIMENTAL
Intervention: Online predilution hemodiafiltration (HDF)
Number of subjects: 146
Study 20813866 — intervention group
Group type: COMPARATOR
Intervention: Conventional hemodialysis (HD)
Number of subjects: 146
Study 18479381 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate (MTA)
Number of subjects: 45
Study 18479381 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium Hydroxide (CH)
Number of subjects: 45
Study 18479381 — intervention group
Group type: COMPARATOR
Intervention: Formocresol (FC)
Number of subjects: 45
Study 20232195 — intervention group
Group type: EXPERIMENTAL
Intervention: Kyphoplasty
Number of subjects: 0
Study 20232195 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertebroplasty
Number of subjects: 0
Study 20232195 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (adequate analgesia, osteoporosis medication, individualized physiotherapy or braces)
Number of subjects: 0
Study 15533635 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipoprotein (a) concentrations during pregnancy
Number of subjects: 0
Study 15533635 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipoprotein (a) concentrations in severe pre-eclampsia
Number of subjects: 0
Study 15533635 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline lipoprotein (a) concentrations
Number of subjects: 0
Study 12211220 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen therapy in postmenopausal women
Number of subjects: 0
Study 12211220 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E therapy to reduce cardiovascular risk
Number of subjects: 0
Study 9756282 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracytoplasmic sperm injection (ICSI)
Number of subjects: 96
Study 9756282 — intervention group
Group type: COMPARATOR
Intervention: In vitro fertilization (IVF)
Number of subjects: 96
Study 7871232 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired presentation method
Number of subjects: 8
Study 7871232 — intervention group
Group type: COMPARATOR
Intervention: Group presentation method
Number of subjects: 8
Study 7871232 — intervention group
Group type: COMPARATOR
Intervention: Staff rankings
Number of subjects: 8
Study 2947783 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 8
Study 2947783 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol
Number of subjects: 8
Study 31314702 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 0
Study 31314702 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 0
Study 28927950 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinect-based real-time audiovisual feedback (AVF) device
Number of subjects: 100
Study 28927950 — intervention group
Group type: COMPARATOR
Intervention: Standing posture
Number of subjects: 100
Study 28927950 — intervention group
Group type: EXPERIMENTAL
Intervention: Kneeling posture
Number of subjects: 100
Study 27289534 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body electromyostimulation (WB-EMS)
Number of subjects: 75
Study 27289534 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body electromyostimulation with dietary supplementation (WB-EMS & P)
Number of subjects: 75
Study 27289534 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 75
Study 23878167 — intervention group
Group type: COMPARATOR
Intervention: IFX dose intensification (5 mg/kg every 4 weeks)
Number of subjects: 69
Study 23878167 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions based on serum IFX and IFX antibody levels using the proposed algorithm
Number of subjects: 69
Study 22076596 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 12
Study 22076596 — intervention group
Group type: COMPARATOR
Intervention: Control (lifestyle modification)
Number of subjects: 12
Study 20823380 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal artery revascularization by stenting
Number of subjects: 0
Study 20823380 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with RAS
Number of subjects: 0
Study 20823380 — intervention group
Group type: COMPARATOR
Intervention: Non-RAS patient controls and normal healthy individuals
Number of subjects: 0
Study 18469151 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-distanced analysis
Number of subjects: 0
Study 18469151 — intervention group
Group type: COMPARATOR
Intervention: Distraction
Number of subjects: 0
Study 18469151 — intervention group
Group type: COMPARATOR
Intervention: Immersed-analysis
Number of subjects: 0
Study 15721999 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 0
Study 15721999 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 0
Study 16285179 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous tumour cell vaccine (n = 9)
Number of subjects: 29
Study 16285179 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 8)
Number of subjects: 29
Study 16285179 — intervention group
Group type: EXPERIMENTAL
Intervention: Open vaccination (n = 12)
Number of subjects: 29
Study 10099746 — intervention group
Group type: EXPERIMENTAL
Intervention: Early obstetrical discharge (24-48 hours)
Number of subjects: 2092
Study 10099746 — intervention group
Group type: COMPARATOR
Intervention: Routine obstetrical discharge
Number of subjects: 2092
Study 10099746 — intervention group
Group type: EXPERIMENTAL
Intervention: Early obstetrical discharge
Number of subjects: 2092
Study 9084515 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% interpleural bupivacaine (10 ml)
Number of subjects: 60
Study 9084515 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 60
Study 1912105 — intervention group
Group type: EXPERIMENTAL
Intervention: m-CPP (up to 80 mg/day for 16 days)
Number of subjects: 8
Study 1912105 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 7046482 — intervention group
Group type: EXPERIMENTAL
Intervention: Printed summary of the computerized medical record during T1 for internists
Number of subjects: 0
Study 7046482 — intervention group
Group type: COMPARATOR
Intervention: Control visits for internists
Number of subjects: 0
Study 7046482 — intervention group
Group type: EXPERIMENTAL
Intervention: Study visits for surgeons
Number of subjects: 0
Study 7046482 — intervention group
Group type: COMPARATOR
Intervention: Control visits for surgeons
Number of subjects: 0
Study 7046482 — intervention group
Group type: EXPERIMENTAL
Intervention: Study visits during T2
Number of subjects: 0
Study 7046482 — intervention group
Group type: COMPARATOR
Intervention: Control visits during T2
Number of subjects: 0
Study 30957646 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementia care mapping for neurorehabilitation (DCM‐NR)
Number of subjects: 41
Study 30957646 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 41
Study 29432379 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 μg kg over 10 min before induction, then 0.4 μg kg h
Number of subjects: 60
Study 29432379 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 μg kg over 10 min before induction, then 0.6 μg kg h
Number of subjects: 60
Study 29432379 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.6 μg kg h
Number of subjects: 60
Study 29432379 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.4 μg kg h
Number of subjects: 60
Study 29432379 — intervention group
Group type: COMPARATOR
Intervention: Control (0.9% saline)
Number of subjects: 60
Study 26766541 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban (5 mg or 2.5 mg twice daily)
Number of subjects: 200
Study 26766541 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (target international normalized ratio, 2‐3)
Number of subjects: 200
Study 26766541 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 200
Study 26766541 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 200
Study 25516016 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg ibuprofen three times a day for three days
Number of subjects: 500
Study 25516016 — intervention group
Group type: COMPARATOR
Intervention: 200 mg mecillinam three times a day for three days
Number of subjects: 500
Study 23649063 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish containing 6% sodium fluoride and 6% calcium fluoride
Number of subjects: 21
Study 23649063 — intervention group
Group type: COMPARATOR
Intervention: Gel containing 6% potassium nitrate and 0.11% fluoride ions
Number of subjects: 21
Study 20970637 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) administration
Number of subjects: 50
Study 20970637 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5% dextrose solution)
Number of subjects: 50
Study 18489783 — intervention group
Group type: EXPERIMENTAL
Intervention: Zafirlukast 20 mg twice daily for 12 weeks (Group I)
Number of subjects: 45
Study 18489783 — intervention group
Group type: EXPERIMENTAL
Intervention: Zafirlukast 20 mg twice daily for 12 weeks (Group II)
Number of subjects: 45
Study 18489783 — intervention group
Group type: COMPARATOR
Intervention: Withdrawal of zafirlukast (both groups)
Number of subjects: 45